The current interest in prodrugs is evident. Since 2008, the FDA has approved over 30 prodrugs, and approximately 10% of all marketed drugs worldwide can be considered prodrugs. Consequently, the success of prodrug strategies are very powerful means to improve formulation and delivery properties of drugs. However, prodrug intervention must be an integral part of the drug design and discovery strategy.
Join Jarkko Rautio of the School of Pharmacy at University of Eastern Finland during this free interactive recording as he demonstrates the versatility of prodrugs strategies in medicinal chemistry to overcome various ADMET barriers (absorption, distribution, metabolism, and excretion) with examples of successful prodrugs developed in industry and in academia.
What You Will Learn
- Why prodrug strategies are often invoked to overcome deficiencies in the physicochemical properties of a drug that limit formulation options
- Why prodrug modifications to improve physicochemical properties can also be used to overcome barriers for ADMET properties
- Why a decision to pursue a prodrug strategy should be done early because the development of a prodrug is usually more complex and less predictable in the clinic than that of other drugs
Co-Producers
;void(0);){kind=link}